• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of molnupiravir for COVID-19 patients.

作者信息

Fatima Maurish, Azeem Saleha, Saeed Junaid, Shahid Abia, Cheema Huzaifa Ahmad

机构信息

Department of Medicine, King Edward Medical University, Lahore, Pakistan.

Department of Medicine, Nishtar Medical University, Lahore, Pakistan.

出版信息

Eur J Intern Med. 2022 Aug;102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.

DOI:10.1016/j.ejim.2022.05.024
PMID:35649740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9130682/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/872f/9130682/4eb54f706d6d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/872f/9130682/4eb54f706d6d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/872f/9130682/4eb54f706d6d/gr1_lrg.jpg

相似文献

1
Efficacy and safety of molnupiravir for COVID-19 patients.莫努匹拉韦对新冠病毒肺炎患者的疗效及安全性
Eur J Intern Med. 2022 Aug;102:118-121. doi: 10.1016/j.ejim.2022.05.024. Epub 2022 May 25.
2
Molnupiravir: A new candidate for COVID-19 treatment.莫努匹韦：COVID-19 治疗的新候选药物。
Pharmacol Res Perspect. 2022 Feb;10(1):e00909. doi: 10.1002/prp2.909.
3
Molnupiravir for the treatment of COVID-19.莫努匹拉韦治疗 COVID-19。
Drugs Today (Barc). 2022 Jul;58(7):335-350. doi: 10.1358/dot.2022.58.7.3419558.
4
Molnupiravir in COVID-19: A systematic review of literature.莫努匹韦治疗 COVID-19：文献系统评价。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.
5
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.基于 N4-羟胞苷的新型缀合物，其体外抗 SARS-CoV-2 和其他人类冠状病毒的抗病毒效力比 EIDD-2801 更强。
Antiviral Res. 2024 May;225:105871. doi: 10.1016/j.antiviral.2024.105871. Epub 2024 Mar 28.
6
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.莫努匹韦：一种针对快速突变的严重急性呼吸综合征冠状病毒 2 的致命诱变药物——叙事性综述。
J Med Virol. 2022 Jul;94(7):3006-3016. doi: 10.1002/jmv.27730. Epub 2022 Apr 2.
7
Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis.莫努匹韦治疗 COVID-19 门诊患者：一项更新的荟萃分析。
J Microbiol Immunol Infect. 2024 Jun;57(3):396-402. doi: 10.1016/j.jmii.2024.03.002. Epub 2024 Mar 16.
8
Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.关于莫努匹韦在 COVID-19 中的全面综述：一种新型有前途的抗病毒药物，以对抗这一大流行病。
Future Microbiol. 2022 Mar;17(5):377-391. doi: 10.2217/fmb-2021-0252. Epub 2022 Feb 24.
9
[Plitidepsin, an inhibitor of the cell elongation factor eEF1a, and molnupiravir an analogue of the ribonucleoside cytidine, two new chemical compounds with intense activity against SARS-CoV-2].普利替德辛，一种细胞延伸因子eEF1a的抑制剂，以及莫努匹拉韦，一种核糖核苷胞苷类似物，两种对严重急性呼吸综合征冠状病毒2具有强效活性的新型化合物
Rev Esp Quimioter. 2021 Oct;34(5):402-407. doi: 10.37201/req/042.2021. Epub 2021 Apr 27.
10
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.莫努匹韦的发现、研发与专利趋势：一种有前景的 COVID-19 口服治疗药物
Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.

引用本文的文献

1
Colchicine for the treatment of patients with COVID-19: an updated systematic review and meta-analysis of randomised controlled trials.秋水仙碱治疗 COVID-19 患者：随机对照试验的更新系统评价和荟萃分析。
BMJ Open. 2024 Apr 17;14(4):e074373. doi: 10.1136/bmjopen-2023-074373.
2
for the treatment of COVID-19 patients: A rapid systematic review and meta-analysis of randomized controlled trials.用于治疗新冠肺炎患者：一项随机对照试验的快速系统评价和荟萃分析
Food Sci Nutr. 2023 Dec 27;12(3):2061-2067. doi: 10.1002/fsn3.3906. eCollection 2024 Mar.
3
Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis.

本文引用的文献

1
Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19.莫努匹拉韦或安慰剂用于新冠肺炎住院患者的随机试验
NEJM Evid. 2022 Feb;1(2):EVIDoa2100044. doi: 10.1056/EVIDoa2100044. Epub 2021 Dec 16.
2
Molnupiravir and Its Antiviral Activity Against COVID-19.莫努匹韦及其抗 COVID-19 的抗病毒活性。
Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022.
3
Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
益生菌用于预防和治疗新型冠状病毒肺炎：一项快速系统评价和荟萃分析
Front Nutr. 2023 Oct 27;10:1274122. doi: 10.3389/fnut.2023.1274122. eCollection 2023.
4
Efficacy and Safety of Molnupiravir Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.莫努匹韦治疗 COVID-19 的疗效和安全性：一项随机对照试验的系统评价和荟萃分析。
Int J Antimicrob Agents. 2023 Aug;62(2):106870. doi: 10.1016/j.ijantimicag.2023.106870. Epub 2023 May 26.
5
Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.莫努匹韦治疗 SARS-CoV-2 感染的疗效和安全性：系统评价和荟萃分析。
J Antimicrob Chemother. 2023 Jul 5;78(7):1586-1598. doi: 10.1093/jac/dkad132.
6
Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.莫努匹韦治疗成人轻或中度 COVID-19：随机对照试验的系统评价和荟萃分析。
Clin Microbiol Infect. 2023 Aug;29(8):979-999. doi: 10.1016/j.cmi.2023.04.014. Epub 2023 Apr 20.
7
Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A Meta-Analysis.莫努匹韦治疗奥密克戎变异株流行期间成年患者轻至中度 COVID-19 的真实世界临床结局：一项荟萃分析
Antibiotics (Basel). 2023 Feb 15;12(2):393. doi: 10.3390/antibiotics12020393.
8
Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.香港一项全人群回顾性队列研究显示，接受口服抗病毒药物治疗的 COVID-19 住院患者病毒载量反弹。
Lancet Infect Dis. 2023 Jun;23(6):683-695. doi: 10.1016/S1473-3099(22)00873-8. Epub 2023 Feb 13.
9
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：一篇强调其进化与治疗方法的最新综述
Vaccines (Basel). 2022 Dec 14;10(12):2145. doi: 10.3390/vaccines10122145.
10
Development and Validation of a Questionnaire to Assess Knowledge and Attitudes toward COVID-19 Preventive Measures in Romania.罗马尼亚一份评估对COVID-19预防措施的知识和态度的问卷的开发与验证
Healthcare (Basel). 2022 Sep 21;10(10):1827. doi: 10.3390/healthcare10101827.
口服抗 SARS-CoV-2 感染药物的可及性和需要采取伦理处方方法。
Lancet Infect Dis. 2022 Aug;22(8):e231-e238. doi: 10.1016/S1473-3099(22)00119-0. Epub 2022 Mar 29.
4
What will be the role of molnupiravir in the treatment of COVID-19 infection?莫努匹韦在治疗新冠病毒感染中会起到什么作用？
Drugs Ther Perspect. 2021;37(12):579-580. doi: 10.1007/s40267-021-00879-2. Epub 2021 Nov 5.
5
Molnupiravir in COVID-19: A systematic review of literature.莫努匹韦治疗 COVID-19：文献系统评价。
Diabetes Metab Syndr. 2021 Nov-Dec;15(6):102329. doi: 10.1016/j.dsx.2021.102329. Epub 2021 Oct 30.
6
Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.莫努匹韦的发现、研发与专利趋势：一种有前景的 COVID-19 口服治疗药物
Molecules. 2021 Sep 24;26(19):5795. doi: 10.3390/molecules26195795.
7
Letter to the Editor in Response to Zhou et al.致编辑的信：回应周等人的文章
J Infect Dis. 2021 Oct 28;224(8):1442-1443. doi: 10.1093/infdis/jiab362.